A Phase 1, Open-label Study of PIPE-307 to Determine Muscarinic Type I Receptor (M1AChR) Occupancy Parameters by [11C] PIPE-307 PET Imaging in Healthy Volunteers
Latest Information Update: 12 Jan 2024
At a glance
- Drugs PIPE-307 (Primary) ; PIPE-307 (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Contineum Therapeutics; Pipeline Therapeutics
- 13 Dec 2023 According to Contineum Therapeutics media release, Pipeline Therapeutics has changed its name to Contineum Therapeutics
- 01 Dec 2021 Status changed from recruiting to completed.
- 17 Nov 2021 Status changed from not yet recruiting to recruiting.